Glenmark launches anti-platelet drug for heart patients
April 29th, 2010 - 7:20 pm ICT by IANSNew Delhi, April 29 (IANS) Glenmark Pharmaceuticals Thursday said it has launched in India an oral anti-platelet drug for patients who have undergone an angioplasty procedure to open up a blocked heart artery.
The drug, whose market size is estimated to be Rs.300 crore, will be sold in India by the company as ‘Aplet’, it said in a statement.
The medicine offers an effective alternative to current oral anti-platelet drugs which have several limitations, including slow onset of action and possibility of poor or no response in diabetic patients.
Clinical studies show the drug helps reduce the risk of a future heart-related event such as a heart attack.
“Glenmark will continue its efforts of introducing first to market products across therapeutic categories in the country,” said Rajeev Sibal, the company’s vice president (India Formulations).
- World's first bedside genetic test developed - Mar 30, 2012
- HIV drug now available as oral powder for children - Jan 29, 2012
- Glenmark recalls 7 lots of oral contraceptives in US - Feb 26, 2012
- Goose launches Artwork Manager for pharma industry - Jan 03, 2012
- Top 10 major advances in heart disease in 2010 - Dec 22, 2010
- New way to treat heart blocks: Drug eluting balloon - Sep 18, 2011
- Patient who underwent angioplasty at 94, steps into 100th year - Nov 25, 2010
- First Chinese herbal drug to enter EU market - Apr 19, 2012
- Simulator to test blood platelets in virtual heart attacks invented - Jun 21, 2010
- Ranbaxy, Russian region sign healthcare pact - Jan 31, 2011
- Orchid Chemicals to invest Rs.200 crore this fiscal - Jul 29, 2011
- Heart saved through the wrist - Mar 13, 2011
- Lust for mega-profits fuels drive for female viagra - Sep 28, 2010
- Gout drug shows promise against angina - Jun 08, 2010
- Gujarat firm to produce nausea preventing nasal spray - Jan 18, 2011
Tags: angioplasty procedure, april 29, crore, diabetic patients, drugs, glenmark pharmaceuticals, heart artery, heart attack, heart patients, India, medicine, New Delhi, related event, risk, slow onset, therapeutic categories, vice president